TABLE 4.
Frequency | ||||
---|---|---|---|---|
Anti-TNFα agent used | ||||
Infliximab | 48.6% (36) | |||
Etanercept | 32.4% (24) | |||
Adalimumab | 18.9% (14) | |||
Duration of treatment (months) | ||||
Mean | 22.06±15.7 | |||
Frequency | ||||
---|---|---|---|---|
Anti-TNFα agent used | ||||
Infliximab | 48.6% (36) | |||
Etanercept | 32.4% (24) | |||
Adalimumab | 18.9% (14) | |||
Duration of treatment (months) | ||||
Mean | 22.06±15.7 | |||